BACKGROUND Primary aldosteronism (PA) plus subclinical Cushing's syndrome (SCS), PASCS, has occasionally been reported. We aimed to clinically characterize patients with PASCS who are poorly profiled. METHODS A population-based, retrospective, single-center, observational study was conducted in 71 patients (age, 58.2 ± 11.2 years; 24 males and 47 females) who developed PA (n = 45), SCS (n = 12), or PASCS (n = 14). The main outcome measures were the proportion of patients with diabetes mellitus (DM), serum potassium concentration, and maximum tumor diameter (MTD) on the computed tomography (CT) scans. RESULTS The proportion of DM patients was significantly greater in the PASCS group than in the PA group (50.0% vs. 13.9%, p <  0.05), without a significant difference between the PASCS and SCS groups. Serum potassium concentration was significantly lower in the PASCS group than in the SCS group (3.2 ± 0.8 mEq/L vs. 4.0 ± 0.5 mEq/L; p <  0.01), without a significant difference between the PASCS and PA groups. Among the 3 study groups of patients who had a unilateral adrenal tumor, MTD was significantly greater in the PASCS group than in the PA group (2.7 ± 0.1 cm vs. 1.4 ± 0.1 cm; p <  0.001), without a significant difference between the PASCS and SCS groups. CONCLUSIONS Any reference criteria were not obtained that surely distinguish patients with PASCS from those with PA or SCS. However, clinicians should suspect the presence of concurrent SCS in patients with PA when detecting a relatively large adrenal tumor on the CT scans.

中文翻译：

---

原发性醛固酮增多症加亚临床库欣综合征患者的临床特征。

背景技术原发性醛固酮增多症（PA）加上亚临床库欣综合征（SCS）PASCS已有报道。我们的目标是对临床特征较差的PASCS患者进行临床表征。方法对71名发展为PA（n = 45），SCS（n = 12）或PA的患者（年龄，58.2±11.2岁； 24例男性和47例女性）进行了基于人群的回顾性单中心观察性研究。 PASCS（n = 14）。主要的预后指标是计算机断层扫描（CT）扫描中患有糖尿病（DM），血清钾浓度和最大肿瘤直径（MTD）的患者比例。结果PASCS组的DM患者比例明显高于PA组（50.0％比13.9％，p <0.05），而PASCS和SCS组之间无显着差异。PASCS组的血清钾浓度显着低于SCS组（3.2±0.8 mEq / L与4.0±0.5 mEq / L； p <0.01），而PASCS和PA组之间无显着差异。在3个患有单侧肾上腺肿瘤的患者的研究组中，PASCS组的MTD显着大于PA组（2.7±0.1 cm对1.4±0.1 cm； p <0.001），两者之间无显着差异。 PASCS和SCS组。结论未获得任何可肯定地区分PASCS患者和PA或SCS患者的参考标准。但是，当在CT扫描中检测到相对较大的肾上腺肿瘤时，临床​​医生应该怀疑PA患者同时存在SCS。在PASCS和PA组之间没有显着差异。在3个患有单侧肾上腺肿瘤的患者的研究组中，PASCS组的MTD显着大于PA组（2.7±0.1 cm对1.4±0.1 cm； p <0.001），两者之间无显着差异。 PASCS和SCS组。结论未获得任何可肯定地区分PASCS患者和PA或SCS患者的参考标准。但是，当在CT扫描中检测到相对较大的肾上腺肿瘤时，临床​​医生应该怀疑PA患者同时存在SCS。在PASCS和PA组之间没有显着差异。在3个患有单侧肾上腺肿瘤的患者的研究组中，PASCS组的MTD显着大于PA组（2.7±0.1 cm对1.4±0.1 cm； p <0.001），两者之间无显着差异。 PASCS和SCS组。结论未获得任何可肯定地区分PASCS患者和PA或SCS患者的参考标准。但是，当在CT扫描中检测到相对较大的肾上腺肿瘤时，临床​​医生应该怀疑PA患者同时存在SCS。在PASCS和SCS组之间没有显着差异。结论未获得任何可肯定地区分PASCS患者和PA或SCS患者的参考标准。但是，当在CT扫描中检测到相对较大的肾上腺肿瘤时，临床​​医生应该怀疑PA患者同时存在SCS。在PASCS和SCS组之间没有显着差异。结论未获得任何可肯定地区分PASCS患者和PA或SCS患者的参考标准。但是，当在CT扫描中检测到相对较大的肾上腺肿瘤时，临床​​医生应该怀疑PA患者同时存在SCS。